Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 22

Revolution Medicines, BeOne Team Up on RAS Cancer Drug

Aug 11, 2026
Revolution Medicines and BeOne Medicines are joining forces to test new drug combinations aimed at cancers driven by RAS mutations, while also expanding access to Revolution Medicines’…
Read More...

Energenesis, Taiwan Tanabe Partner on Diabetic Foot Ulcer Drug

Aug 10, 2026
Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku to advance ENERGI-F703DFU, an experimental topical treatment being developed for diabetic foot…
Read More...

New Era for Autoimmune T-Cell Engagers Takes Centre Stage This October

Aug 5, 2026
Autoimmune T-Cell Engager Field Reaches Defining Moment as Industry Leaders Prepare to Unite in Boston Boston, MA | October 27–29, 2026 The autoimmune T-cell engager field is…
Read More...

Fujifilm and Taiho Partner on Next-Generation ADC Manufacturing

Aug 5, 2026
FUJIFILM Corporation and Taiho Pharmaceutical have formed a strategic partnership to advance manufacturing technologies for next-generation antibody-drug conjugates (ADCs), aiming to…
Read More...

Amplia and Lilly Partner on Lung Cancer Combination Trial

Aug 5, 2026
Amplia Therapeutics has entered into a clinical trial collaboration with Eli Lilly and Company to evaluate a new targeted treatment combination for patients with advanced non-small cell…
Read More...

FDA Grants Breakthrough Status to Lilly’s Pancreatic Cancer Drug

Aug 5, 2026
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the…
Read More...

Supernus and Indivior Announce Merger to Create CNS Drug Leader

Aug 5, 2026
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to combine in a tax-free, all-stock merger of equals that will create a leading biopharmaceutical company focused on…
Read More...

Curium to Acquire Lantheus in $8 Billion Radiopharma Deal

Aug 4, 2026
Curium and Lantheus have announced a definitive agreement to combine their businesses in a deal valued at up to approximately $8 billion, creating one of the world's largest…
Read More...

Ratio Therapeutics Raises $70 Million to Advance Cancer Radiopharmaceuticals

Aug 3, 2026
Ratio Therapeutics has secured $70 million in Series C financing to accelerate the development of its radiopharmaceutical pipeline, advance clinical trials, and expand its manufacturing…
Read More...

IMPACT Partners Pharmanovia to Expand Senaparib Across 66 Countries

Aug 3, 2026
IMPACT Therapeutics has signed an exclusive licensing agreement with global specialty pharmaceutical company Pharmanovia to expand the reach of its ovarian cancer treatment, senaparib,…
Read More...
Previous 1 … 20 21 22 23 24 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.